Amgen Inc
AMGN Company Profile
Current Price
$388.16
Health Care
Biotechnology
California; U.S.A
31.5K
1983
Business Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Company Information
Analyze AMGN Stock
Get comprehensive financial analysis, real-time data, and AI-powered insights
Frequently Asked Questions
What does AMGN do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, an...
What industry is AMGN in?
Amgen Inc operates in the Biotechnology industry within the Health Care sector.
Where is AMGN headquartered?
Amgen Inc is headquartered in California; U.S.A.
How many employees does AMGN have?
Amgen Inc has approximately 31.5K employees.
Who is the CEO of AMGN?
Executive leadership information for AMGN is available through company filings and our platform.
When was AMGN founded?
Amgen Inc was founded in 1983.
What is AMGN's business model?
Amgen Inc operates in the Biotechnology industry generating revenue through its core business operations in the Health Care sector. View our detailed financial analysis for revenue breakdown and business segments.
Is AMGN publicly traded?
Yes, AMGN (Amgen Inc) is a publicly traded company listed on NASDAQ. You can view real-time stock quotes, financial statements, and analysis on our platform.
Disclaimer: Company information is sourced from public filings and data providers. Information may change as companies update their corporate structure, operations, and disclosures. Always verify current information through official company sources and SEC filings.